SR ONE CAPITAL MANAGEMENT, LP - Q1 2024 holdings

Add to watchlist

$364 Million is the total value of SR ONE CAPITAL MANAGEMENT, LP's 6 reported holdings in Q1 2024. The portfolio turnover from Q4 2023 to Q1 2024 was 20.0% .

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
SellARCELLX INC$163,208,117
-6.5%
2,346,630
-25.4%
44.83%
-38.9%
CRSP NewCRISPR THERAPEUTICS AGnamen akt$71,496,500–1,048,951
+100.0%
19.64%–
SBTX  ARS PHARMACEUTICALS INC$41,011,869
+86.5%
4,012,9030.0%11.26%
+22.0%
NKTX BuyNKARTA INC$36,033,330
+309.5%
3,333,333
+150.0%
9.90%
+167.8%
DSGN  DESIGN THERAPEUTICS INC$26,301,698
+52.1%
6,526,4760.0%7.22%
-0.5%
BuyMINERALYS THERAPEUTICS INC$26,037,172
+68.7%
2,016,822
+12.4%
7.15%
+10.4%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2024-05-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
DESIGN THERAPEUTICS INC11Q2 202468.1%
ARCELLX INC.10Q2 202473.3%
NKARTA INC.9Q2 20249.9%
EFFECTOR THERAPEUTICS INC8Q3 202331.9%
ARS PHARMACEUTICALS INC7Q2 202411.6%
MINERALYS THERAPEUTICS INC6Q2 202413.2%
CRISPR THERAPEUTICS AG2Q2 202419.6%
Alumis Inc.1Q2 20248.2%
enGene Holdings Inc.1Q2 20241.5%
KALA Bio, Inc.1Q2 20241.0%

View SR ONE CAPITAL MANAGEMENT, LP's complete holdings history.

Latest filings
TypeFiled
N-PX2024-08-27
13F-HR2024-08-13
13F-HR2024-05-13
13F-HR2024-02-12
13F-HR2023-11-13
13F-HR2023-08-10
13F-HR/A2023-05-19
13F-HR2023-05-09
13F-HR2023-02-08
13F-HR2022-11-08

View SR ONE CAPITAL MANAGEMENT, LP's complete filings history.

All filings

View complete filings history.

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (364088685.0 != 364088686.0)

Export SR ONE CAPITAL MANAGEMENT, LP's holdings

CSVXLS